Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer

Related Experiment Video

Updated: Apr 12, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Christine Zhang, Atheena Ben, Jade Reville

  • 1Department of Microbiology, Immunology, Saint James School of Medicine, A-I-2640 Albert Lake Drive, The Quarter, P.O. Box 318, Anguilla BWI, Anguilla. sdasgupta@mail.sjsm.org.

Anti-Cancer Agents in Medicinal Chemistry
|May 19, 2015
PubMed

Insights

Toll-like receptor (TLR) signals offer a promising new avenue for breast cancer therapy. TLR agonists activate immune cells to destroy cancer cells, complementing existing treatments like selective estrogen receptor modulators (SERMs).

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Breast cancer onset is multifactorial, with conventional treatments including anti-estrogen drugs and selective estrogen receptor modulators (SERMs).
  • Immunotherapy presents a modern approach, with toll-like receptor (TLR) signals emerging as a significant area of investigation.
  • TLR signals are implicated in regulating the tumor suppressor p53 gene.

Purpose of the Study:

  • To explore the potential of toll-like receptor (TLR) signals in developing novel breast cancer therapies.
  • To highlight the role of TLR agonists in immune cell activation and cancer cell destruction.

Main Methods:

  • Review of recent investigations into TLR signal significance in breast cancer.
  • Analysis of TLR agonist capabilities in immune cell activation and cytotoxicity induction.

Main Results:

  • TLR agonists activate natural killer cells, CD8 T cells, B cells, and interferons, inducing cellular cytotoxicity.
  • TLR signals contribute to the intra-tumoral generation of cellular cytotoxicity, promoting apoptosis and tumor cell destruction.

Conclusions:

  • TLR signals represent a promising prospect for innovative breast cancer therapy development.
  • The activation of immune responses via TLR agonists offers a localized approach to tumor destruction, impacting immunotherapy strategies.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K